Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03636854 Not yet recruiting - Healthy Clinical Trials

Quadriceps Concentric vs Eccentric

Start date: October 2018
Phase: N/A
Study type: Interventional

The aim of the study is to compare the effects of concentric and eccentric exercises on muscle strength, muscle thickness and balance in healthy Individuals. Participants will randomly be divided into 2 groups: Concentric exercise (CE) group, eccentric exercise (EE) group. Concentric exercise group will be doing 2 concentric exercises and eccentric exercise group will be doing 2 eccentric exercise for 8 weeks. The evaluations will be repeated after 8 weeks of training to reveal the effects of concentric and eccentric exercises.

NCT ID: NCT03636204 Not yet recruiting - Healthy Clinical Trials

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin Mutation

Start date: September 15, 2018
Phase: Phase 1
Study type: Interventional

A first in human phase 1, single dose and multiple dose study in healthy volunteers and Granulin mutation causative of frontotemporal dementia to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics

NCT ID: NCT03635502 Not yet recruiting - Healthy Clinical Trials

MOTOR IMAGERY ABILITY IN PATIENTS WITH STROKE: A CONTROLLED STUDY

Start date: August 2018
Phase:
Study type: Observational

Motor imagery (MI) might be described as a dynamic process in which an individual mentally stimulates an action without any overt movement. After stroke, motor imagery ability is impaired and also due to structure of MI, not every stroke patients is able to perform MI. Therefore, the aim of the study is a) to compare the motor imagery ability of stroke patients and healthy participants, b) to define motor imagery ability of stroke patients in accordance with their demographical and clinical features.

NCT ID: NCT03635047 Not yet recruiting - Healthy Clinical Trials

A Phase I Study for Safety and Tolerability of AL002 in Healthy and Mild to Moderate Alzheimer's Disease Participants

Start date: November 2018
Phase: Phase 1
Study type: Interventional

This is a multi-centre, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AL002.

NCT ID: NCT03632408 Not yet recruiting - Healthy Clinical Trials

Hangover and Residual Zopiclone Effect on Spatial Perception

SEKO-A
Start date: September 2018
Phase: Phase 1
Study type: Interventional

Hangover after recreational alcohol use, residual effect of zopiclone and placebo compared in terms of spatial perception, psychomotor tests and simulated driving ability. Three recording visits plus screening included.

NCT ID: NCT03630679 Not yet recruiting - Healthy Clinical Trials

A Study Evaluating Sleep, Stress and Infant Nutrition Using a Chatbot

Start date: August 2018
Phase:
Study type: Observational

20 parents with healthy preterm infants (born at <37 weeks of gestation), age 0-6 months and discharged from the hospital at time of enrollment and 20 parents with healthy full-term infants (born at ≥37 weeks of gestation), age 0-6 months and discharged from the hospital at time of enrollment will be enrolled to obtain records of sleep, stress, and infant nutrition from parents of infants (preterm and full-term) through interaction with the study chatbot.

NCT ID: NCT03629223 Not yet recruiting - Healthy Clinical Trials

Bioequivalence of Tablet Formulation 3 (TF3) and Tablet Formulation 2 (TF2) and Effect of Food on the Pharmacokinetics (PK) of Tepotinib

Start date: August 28, 2018
Phase: Phase 1
Study type: Interventional

The study will demonstrate bioequivalence between the new tablet formulation (TF3, test treatment) and the tablet formulation used in clinical studies (TF2, reference treatment) and will investigate effect of food on PK of tepotinib.

NCT ID: NCT03629054 Not yet recruiting - Healthy Clinical Trials

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

Start date: August 27, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this trial is to establish the bioequivalence of two empagliflozin/linagliptin/metformin extended release (XR) fixed dose combination (FDC) tablets (Test, T) compared with the same doses of the individual components given in separate tablets (Reference, R) when administered together after a high-fat, high-calorie meal.

NCT ID: NCT03628339 Not yet recruiting - Healthy Clinical Trials

Effect of Tepotinib on Pharmacokinetics (PK) of Cytochrome P450 (CYP) 3A Substrate Midazolam

Start date: August 20, 2018
Phase: Phase 1
Study type: Interventional

The study will investigate the effect of tepotinib on the PK of the CYP3A substrate midazolam determined from concentrations of midazolam and its main metabolite 1-hydroxymidazolam in healthy participants.

NCT ID: NCT03627351 Not yet recruiting - Healthy Clinical Trials

Sensory Evaluation of the Taste of Pediatric Medicines

MEDTASTE
Start date: September 1, 2018
Phase:
Study type: Observational

The investigators will conduct a systematic study of the sensory perception of a diverse set of commonly used pediatric liquid medications and excipients in tandem with an equally complete genetic analysis of the adult sensory panelists to investigate the relationship between genetic variation and individual differences in the perceived flavor (taste, smell, irritation) of pediatric medicines. The flavor of each medicine and excipient will be measured individually using both cognitively demanding methods unsuitable for young children and simpler measures validated for use by children. Salivary DNA samples will be collected to carry out genome wide association study (GWAS).